Biotechnology

The IPO boom in Hong Kong is extending beyond technology, according to the HKEX CEO. As fundraising tops $40 billion, firms from various sectors such as biotechnology, mining, and consumer companies are also reported to be in the pipeline.

Milestone Pharmaceuticals Inc. reported a loss of $28.6 million and 21 cents per share for its second quarter, missing Wall Street expectations. The company also posted revenue of $559,000, which fell short of the three-analyst forecast of $800,000.

The article argues that biotechnology is a critical component of national power, with China strategically investing in areas like artificial intelligence, synthetic biology, and precision medicine. It suggests the U.S. Department of Veterans Affairs (VA) could play a role in helping America compete with China in this field.

China's growing influence as a biotechnology innovation hub has raised strategic concerns in the United States, prompting policymakers to reassess responses. A leading analytics firm's report highlights implications for pharmaceutical supply-chain resilience, economic competitiveness, and national security.

China has lured away 105 top American experts, with nearly half specializing in biotechnology and medicine, as part of its strategy to surpass the United States in medical innovation.

Axiom Biosciences is considering a Hong Kong initial public offering, a rare move for an American biotechnology firm. The IPO aims to leverage China's growing clinical development capabilities in the biotech sector.

A U.S. congressional advisory panel delegation is visiting China for the first time in seven years to assess how the economic and trade relationship between the two countries impacts national security. The US-China Economic and Security Review Commission plans meetings with Chinese government officials, academics, industry leaders in AI, biotechnology, and robotics, as well as U.S. diplomats.

CPEC 2.0 represents a strategic shift from infrastructure-focused investments to market-driven economic cooperation between Pakistan and China. The initiative integrates Pakistan's '5Es' policy with China's 'Five Corridors' framework, aiming to boost exports, technological collaboration, and private sector engagement while addressing macroeconomic and security challenges.

Mainland Chinese institutional fund managers have increased investments in Hong Kong-listed biotechnology stocks due to attractive valuations and a surge in cross-border licensing deals. E Fund Management, China's largest mutual fund manager, acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing 91,500 shares at HK$46.90 each.

US lawmakers are pushing for increased scrutiny of Chinese investment in pharmaceuticals and biotechnology. A bipartisan Senate bill aims to enhance transparency in foreign influence within the pharmaceutical industry, driven by concerns over US dependence on China for critical drug ingredients and medical supply chains.

The US-China technology rivalry is expanding into biotechnology, with export controls and investment restrictions creating a new strategic competition front. East Asia's push for biotech autonomy risks slowing innovation, highlighted by a 2025 US restriction on China's access to advanced biotechnology equipment.

Biotechnology is highlighted as crucial for human well-being and sustainable development. The article emphasizes that restoring and conserving plant and animal resources is essential for achieving the United Nations' Sustainable Development Goals.

Legislators are pushing to expand the COINS Act to include biotechnology, allowing the U.S. government to restrict investments in the Chinese biotech industry. Venture capitalist Julie Grant opposes these restrictions, arguing they would hinder U.S. drug development and harm patients by disrupting decades-long industry interdependencies.

Europe risks losing its leadership in the pharmaceutical sector due to geopolitical challenges and internal indifference, with the United States' Most-Favored-Nation pricing policy and China's rapid advancements in biotechnology and innovation exacerbating the decline. Europe lags behind in clinical trials, R&D spending, and attracting investment compared to the US and China.

The US-China geopolitical rivalry may expand into biotechnology, with American pharmaceutical firms relying on China's growing industry for drug candidates. China's biotech sector, previously seen as a low-cost manufacturing hub, has gained momentum through sustained investment and faster development.

The Hong Kong government's offshore yuan-denominated venture capital fund, led by Hong Kong Investment Corporation (HKIC), is expected to attract investors targeting artificial intelligence, biotechnology, and new energy sectors. Financial Secretary Paul Chan Mo-po announced the initiative, highlighting HKIC's role in managing the fund.

Revolution Medicines' pancreatic cancer drug daraxonrasib showed a 60% reduction in mortality risk compared to chemotherapy, with a median survival of 13.2 months. China's biotechnology sector is rapidly growing, marked by a first-ever China-only clinical trial presentation at the ASCO conference.

Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.

AI tools are improving at designing pathogens, which could potentially enable bioterrorism. Leading models are getting better at this task. This raises concerns about the potential misuse of AI in biotechnology.

The article highlights the critical need for reliable botanical data to advance AI in biotechnology, emphasizing that human taxonomic expertise remains essential despite growing reliance on artificial intelligence. It warns that the decline of human expertise could hinder progress in this field.